R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed
  • Phase

    Phase 2
  • Study Type

  • Study Participants

Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
Assess the combination of efficacy and safety of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma who are refractory or in relapse.
Study Started
Jul 31
Primary Completion
Dec 31
Study Completion
Jul 31
Results Posted
Nov 01
Last Update
Nov 01

Drug Rituximab, Bendamustine, Mitoxantrone, Dexamethasone

Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv

  • Other names: R-BMD

R-BMD Experimental

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years


Inclusion Criteria:

Age ≥ 18 and ≤ 75 years.
Patients with follicular lymphoma grade 1, 2 or 3a, CD20 +, histologically confirmed lymph node biopsy or tissue. Be accepted diagnosis in bone marrow if no accessible lymph nodes and whether it has discarded the mantle LLC, and NHL.
Follicular lymphoma patients treated with the combination of rituximab and chemotherapy in first line, which have been refractory or relapsed after having achieved any responses to this first line of pretreatment (excluding radiotherapy).
ECOG ≤ 2.
Signed written informed consent.

Exclusion Criteria:

Clinical suspicion or documentation of histological transformation.
Have received prior chemotherapy scheme, first line without Rituximab.
Prior autologous or allogeneic.
CNS infiltration by LF (primary CNS lymphoma or lymphomatous meningitis).
Past or active Hepatitis B (at least one of the following markers HBsAg, HBe Ag, anti-HBc, HBV DNA)
HCV infection. HIV infection or other conditions of serious immunosuppression.
Previous neoplasms except non-melanoma skin cancer of the cervix or adequately treated.
Cardiac function in cardiac patient known or prior treatment with anthracyclines with EF <50%.
Impaired renal function (creatinine> 1.5 x Upper Limit of Normal, LSN) or a creatinine clearance <50 ml / h, not related to lymphoma.
Impaired liver function (bilirubin, AST / ALT or GGT> 2 x ULN) were not related to lymphoma.
Women who are nursing or pregnant. Women of childbearing potential will be included prior pregnancy test serum / urine negative. Use effective contraception to be kept for 1 year after cessation of rituximab.
Patients with heart disease, pulmonary, neurological, psychiatric or severe metabolic and not secondary to lymphoma.
Severe acute or chronic infection in activity.
Any other concurrent medical or psychological comorbidity that might interfere with participation in this study.


Rituximab, Bendamustine, Mitoxantrone, Dexamethasone

All Events

Event Type Organ System Event Term Rituximab, Bendamustine, Mitoxantrone, Dexamethasone

Response Rate

The primary endpoint is the number of Participants with Response according to the criteria of the International Workshop to Standardize Response Criteria for NHL Complete Remission (CR): Nodes returned to normal (if GTD >15 mm before therapy, GTD now ≤15 mm; if GTD 11-15 and SA >10 mm before therapy, SA now ≤10 mm) All (non-nodal) target lesions completely resolved Partial Remission (PR) SPD of target lesions decreased ≥50% from baseline Spleen and liver nodules regress by 50% in SPD or single lesion in GTD Stable Disease (SD) Not enough shrinkage for PR Not enough growth for PD Progressive Disease (PD): SPD increase ≥50% from nadir (smallest value seen during trial) in nodal target lesions overall or in any single nodal target lesion

Induction Rituximab, Bendamustine, Mitoxantrone, Dexamethasone

Maintenance Rituximab

Secondary Endpoints Included an Assessment of the Following Parameters: Progression-Free Survival, Disease-Free Survival, Global Survival, Duration of the Response.


Disease-Free Survival

months (Median)
Full Range: 36.0

Duration of the Response

months (Median)
Full Range: 36.0 to 54.0

Global Survival

Progression-Free Survival

months (Median)
Full Range: 28.0 to 56.0

Age, Continuous

years (Median)
Full Range: 32.0 to 76.0

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone